Kairos Pharma Ltd. (NYSE American: KAPA) announced it has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award highlights the company’s work in advancing cancer therapeutics designed to address treatment resistance, underscoring Kairos’ focus on extending the effectiveness of existing cancer therapies through innovative drug resistance-targeting approaches. The full press release is available at https://ibn.fm/WuBOf.
Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The award from GHP Magazine recognizes Kairos Pharma’s contributions to a critical area of oncology: drug resistance. Cancer cells often develop resistance to therapies, leading to disease progression and relapse. By targeting CD105, Kairos aims to resensitize tumors to existing treatments, potentially offering new options for patients who have exhausted standard therapies. The company’s focus on structural biology and immune suppression mechanisms sets it apart in the competitive oncology landscape.
This recognition comes as Kairos Pharma continues to advance its clinical programs. The Phase 2 trial in prostate cancer and Phase 1 trial in non-small cell lung cancer represent significant milestones. If successful, ENV-105 could become a key component of combination therapies, addressing resistance mechanisms that limit the efficacy of current treatments. The award underscores the importance of innovation in drug resistance, a challenge that affects millions of cancer patients worldwide.
Investors and industry watchers can find the latest news and updates relating to KAPA in the company’s newsroom at https://ibn.fm/KAPA. The award not only validates Kairos Pharma’s scientific approach but also highlights the growing interest in targeting resistance pathways as a strategy to improve cancer outcomes.
